Abstract: The voltage-gated sodium channel is vital for cardiomyocyte function, and consists of a protein complex containing a pore-forming α subunit and two associated β subunits. A fundamental, yet unsolved, question is to define the precise function of β subunits. While their location in vivo remains unclear, large evidence shows that they regulate localization of α and the biophysical properties of the channel. The current data support that one of these subunits, β2, promotes cell surface expression of α. The main α isoform in an adult heart is NaV1.5, and mutations in SCN5A, the gene encoding NaV1.5, often lead to hereditary arrhythmias and sudden death. The association of β2 with cardiac arrhythmias has also been described, which could be due to alterations in trafficking, anchoring, and localization of NaV1.5 at the cardiomyocyte surface. Here, we will discuss research dealing with mechanisms that regulate β2 trafficking, and how β2 could be pivotal for the correct localization of NaV1.5, which influences cellular excitability and electrical coupling of the heart. Moreover, β2 may have yet to be discovered roles on cell adhesion and signaling, implying that diverse defects leading to human disease may arise due to β2 mutations.

Keywords: cardiac arrhythmias; protein trafficking; voltage-gated sodium channel; NaV1.5; SCN2B

1. Introduction

We often wonder why people get sick. Why do some people die early in life while others reach old age without major health problems? It is obvious that both genetic and environmental factors are playing a role. An organ that must certainly remain in perfect condition throughout life is the heart; its abnormal functioning is a sign of diseases that can lead to premature death. An unsolved matter is to determine the molecular alterations that can lead to heart disease and how these may arise.

1.1. Arrhythmias and Sudden Cardiac Death (SCD)

Cardiomyopathies are a type of disease affecting the function of the heart muscle and leading to heart failure. Suffering from cardiomyopathy also implies being at risk of arrhythmia and sudden cardiac death (SCD). In the US alone, SCD affects annually up to 400,000 people, with coronary heart disease being present in 80% of the cases [1]. Importantly, it is estimated that around 6 million people die each year worldwide of SCD due to ventricular arrhythmia, which is often associated with cardiomyopathy (the survival rate of a cardiac arrest is <1%). This represents 1/3rd of deaths from cardiovascular disease of any kind, being these in fact the main cause of death in the world [2]. Therefore, understanding how arrhythmias develop, and the consequences that they entail, has interest in the fields of biology, medicine and socioeconomics.
SCD can occur in people under 50 and be associated with pathologies defined as unexplained or arrhythmogenic. It is often the first and single clinical manifestation of an inherited heart disease that has remained undiagnosed by conventional clinical practice [3]. A well-known arrhythmia is Brugada syndrome (BrS), a disorder characterized by an abnormal electrocardiogram (ECG) that causes ventricular fibrillation. Although considered a rare genetic disease, it is actually inherited by an autosomal dominant trait [4] and linked to a high mortality rate [5]. In BrS, the ventricular muscle quivers, instead of contracting in a coordinated manner. Such tachycardia prevents the blood from flowing efficiently throughout the body. Consequently, the individual faints and can die within a few minutes [6].

Since genetics and molecular biology emerged in the field of clinical cardiology, multiple genes and mutated variants responsible for arrhythmias that lead to SCD were identified. A fundamental hypothesis is that many cases of SCD are the clinical manifestation of rare hereditary diseases caused by mutations in transmembrane ion channels implicated in generating the cardiac action potential (AP). These channelopathies are due to alterations in subunits of the channel protein complex, as well as in associated or regulatory proteins. Therefore, they can be congenital and due to one or more mutations in the genes involved. Along with BrS, other channelopathies that cause SCD include long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia [7].

1.2. The Cardiac Voltage-Gated Sodium (Na\textsubscript{V}) Channel

The voltage-gated sodium (Na\textsubscript{V}) channel often shows alterations leading to cardiac channelopathies [8]. For instance, ~20% of BrS cases are caused by mutations in SCN5A, a gene mapping to the chromosomal region 3p21 [9] and encoding Na\textsubscript{V}1.5, the pore-forming, \(\alpha\) subunit, of the main cardiac Na\textsubscript{V} channel [4]. In the heart, the Na\textsubscript{V} channel is responsible for generating the rising phase of the AP, thus playing a central role in myocardial excitability. The abnormal ECG observed in BrS is due to loss-of-function of the Na\textsubscript{V} channel. It is characterized by an ST segment elevation of the V1-V3 precordial leads and occurs in the absence of structural heart disease [6] (Figure 1).

![Figure 1. Role of Na\textsubscript{V}1.5 in the generation of the cardiac action potential (AP). Schematic representation of the cardiac AP and the contribution of the sodium current (\(I_{Na}\)) generated by Na\textsubscript{V}1.5 as responsible for the rising (depolarization) phase. The electrical pattern of precordial lead V1 of a normal electrocardiogram (ECG) and one with an ST segment elevation typical of BrS are shown (arrow).](image-url)

Initiation of the AP, along with the degree of intercellular communication via gap junctions, to allow propagation, determines the conduction velocity of the electrical impulse. Thus, mutations in
SCN5A have also been associated with LQTS, atrial fibrillation and even cardiomyopathies [10]. In fact, the NaV channel also plays an important role in electrical impulse propagation in the heart [11].

NaV1.5 is located in the sarcolemma, i.e., the cardiomyocyte plasma membrane. Its localization and function are regulated by auxiliary β subunits and other associated proteins [12,13]. Alterations in the channel biophysical properties—including changes in activation or inactivation kinetics—can give rise to the channel’s gain- or loss-of-function [8]. In this context, potentially fatal arrhythmias may be due to defects in regulation of transcription, affecting SCN5A expression, or to post-translational modifications, causing, for example, an incomplete processing of NaV1.5 that may turn into its retention in the exocytic pathway. A precise subcellular location of NaV1.5 is essential for the channel role in AP generation (Figure 2). Thus, defects in NaV1.5 targeting to the sarcolemma—or an incorrect or inadequate anchoring at the membrane—can affect considerably NaV channel functioning. In fact, alterations in these processes are associated with BrS [14].

Figure 2. Alterations in the NaV channel associated with heart disease. Several molecular mechanisms can affect expression, localization or function of the channel and are associated with inherited or acquired heart disease. ER, endoplasmic reticulum.

To understand the role of the NaV channel in cardiac function, and the consequent alterations that may lead to disease, it is essential to study traffic and localization of NaV1.5, and importantly, the contribution of its associated and regulatory proteins. In fact, considerable effort has been made to investigate the pathways that determine the correct location of NaV1.5 to subregions of the sarcolemma. It is known that several proteins interact with NaV1.5, including cytoskeleton components, and various structural domains involved in these interactions have been identified [13,15,16]. In addition, it has been reported the assembly of macromolecular complexes between NaV1.5 and the inward rectifier potassium channel Kir2.1 (which contributes to the final repolarization phase of the AP, and controls the resting membrane potential of ventricular cardiomyocytes), which localize together in microdomains of the sarcolemma, thereby controlling excitability [17]. Interestingly, an unconventional anterograde route between NaV1.5 and Kir2.1/2.2 has been described, which would allow reciprocal regulation of their localization. Understanding these interactions should help determining defects in localization of these channels at the sarcolemma. This is important to subsequently assess the clinical features and
severity of the disease. For instance, depending on the BrS-associated mutation in SCN5A, a different pathological retention of Na\textsubscript{v}1.5 may be observed, either in the endoplasmic reticulum (ER) or in the Golgi apparatus. In this regard, ER-, but not Golgi-retained Na\textsubscript{v}1.5 mutants, can be partially restored by Kir2.1/2.2, thereby ameliorating the I\textsubscript{Na} decrease due to the SCN5A mutation. Thus, Golgi-retained Na\textsubscript{v}1.5 mutants give a comparatively higher decrease in I\textsubscript{Na}, and therefore of cardiac excitability, than the ER-retained mutants [14].

Na\textsubscript{v}1.5 is located at intercalated discs (ID), that is, the region between cardiomyocytes containing cell adhesion complexes, and also in the lateral membrane [13], where costameres and transverse tubules (T tubules) are found; costameres are protein complexes connecting the cardiomyocyte sarcomeres with the extracellular matrix, while T tubules are deep invaginations of the sarcolemma in the Z-disk region (or Z-line, which borders the sarcomeres), allowing electrical coupling with Ca\textsuperscript{2+} release from the sarcoplasmic reticulum [18]. The distribution of Na\textsubscript{v}1.5 in ID and T tubules depends in part on ankyrin-G (AnkG) [19]. In fact, multiple interactions implicating Na\textsubscript{v}1.5 have been described, which establish protein complexes defining different pools of Na\textsubscript{v}1.5 in cardiomyocytes (Figure 3).

Thus, plakophilin 2 (PKP2) and SAP97 (synapse-associated protein 97; a member of the family of membrane-associated guanylate kinases) would control Na\textsubscript{v}1.5 localization at the ID [20]. It has been proposed that PKP2 is part of a complex with connexin 43 (Cx43) and AnkG, possibly independent of the interaction with SAP97 [21]. Na\textsubscript{v}1.5 is also located in the lateral membrane, whose targeting is regulated by the syntrophin/dystrophin complex connected to the actin cytoskeleton [20]. AnkG is also associated with Na\textsubscript{v}1.5 in T tubules [22]. Yet, AnkG is clearly required for Na\textsubscript{v}1.5 targeting to the ID [23]. Finally, it was shown by super-resolution microscopy that a complex formed by Cx43, PKP2 and N-cadherin is responsible for the delivery of microtubule cargo to the ID, including Na\textsubscript{v}1.5; the components and location of this molecular complex define the so-called connexome, which regulates electrical coupling, cell adhesion, and cell excitability [24].

Understanding the distribution of Na\textsubscript{v}1.5 in sarcolemma subdomains has indeed become a complex task. Thus, recent data suggest the presence of a sub-pool of Na\textsubscript{v}1.5 at the lateral membrane that is independent of syntrophin [25]. Interestingly, even the associated β1 subunit (see below) appears differentially localized at sarcolemma subdomains. In this regard, Tyr-phosphorylated β1 (pYβ1) is associated with Na\textsubscript{v}1.5 at the ID, along with other partners, such as AnkG, Cx43 and N-cadherin, whereas non-phosphorylated β1 associates with Nav channels in T tubules [26].

Figure 3. Multiple interactions implicating Na\textsubscript{v}1.5 in cardiomyocytes. Several proteins have been identified interacting with Na\textsubscript{v}1.5 in different subregions of the cardiomyocyte sarcolemma, establishing protein complexes that define different pools of Na\textsubscript{v}1.5. See the text for details.
In summary, Na\textsubscript{V}1.5 is probably grouped into well-defined functional nanodomains in each subregion [27]. In fact, Na\textsubscript{V}1.5 has been found associated with lipid rafts, which are membrane domains rich in cholesterol and glycosphingolipids where ionic channel regulatory proteins concentrate [18]. Understanding how all these molecules interact to regulate the subcellular localization of Na\textsubscript{V} channels is clearly a challenge in this field of research.

1.3. The Na\textsubscript{V} Channel \(\beta\) Subunits

Analysis of Na\textsubscript{V}1.5 trafficking can be envisaged from at least three standpoints. First, we must understand how Na\textsubscript{V}1.5 is targeted to cell surface domains; secondly, how Na\textsubscript{V}1.5 is retained in certain subregions or domains of the sarcolemma, thereby defining its surface distribution; and third, how Na\textsubscript{V}1.5 endocytosis and turnover are regulated, allowing renewal of the channel at the surface. In this review, we will deal primarily with the first two points, focusing on a Na\textsubscript{V} channel-associated \(\beta\) subunit, namely \(\beta\)2. The \(\beta\) subunit family consists of four genes, SCN1B-SCN4B, which encode four different proteins, \(\beta\)1–4, of which \(\beta\)1 has two alternative splice variants, \(\beta\)1A and \(\beta\)1B; \(\beta\) subunits regulate sodium current (\(I_{Na}\)) density [28]. Interacting with Na\textsubscript{V}1.5 by its extracellular region [29], or even through the transmembrane domain (TMD) [30], it has been proposed that they perform a major role mainly in ensuring efficient transport of the channel’s \(\alpha\) subunit to the plasma membrane [13]. Interestingly, several BrS-associated mutations causing loss-of-function of the Na\textsubscript{V} channel have been found in \(\beta\) subunits [31–34].

The current view on the function of \(\beta\) subunits within the Na\textsubscript{V} channel is that (i) they determine proper cell surface localization of the channel complex, (ii) they control channel gating and kinetics, and also (iii) they regulate gene expression of the \(\alpha\) subunit, and perhaps of the \(\beta\) subunits themselves [12]. The mechanisms by which \(\beta\) subunits may carry into effect these roles have been addressed in excellent recent reviews [35–37]. However, the data lead to the conclusion that modulation of Na\textsubscript{V} channels by \(\beta\) subunits in heterologous systems shows effects that are dependent on the \(\beta\) and \(\alpha\) subunits analyzed and, importantly, also of the cell type, which may be related to endogenous expression of some of the subunits. Indeed, it has been seen that in neurons or cardiomyocytes obtained from null mice, which would be more physiologically relevant models, the reported effects are in general less striking. Moreover, the protein domain(s) of \(\beta\) interacting with \(\alpha\), and posttranslational modifications, such as glycosylation and phosphorylation, clearly have an effect. In this regard, glycosylation of \(\beta\) subunits, and in particular sialylation, was found important for regulating the channel biophysical properties. Specifically, only sialylated \(\beta\)1 shifted gating of Na\textsubscript{V}1.2 and Na\textsubscript{V}1.5. On the other hand, sialylation of \(\beta\)2 influenced Na\textsubscript{V}1.5 gating, while not that of Na\textsubscript{V}1.2; those data also implicated that effects by these subunits on \(\alpha\) are synergistic and, for \(\beta\)2 in particular, isoform specific [38].

The possibility that \(\beta\) subunits may compensate for each other in vivo adds another level of complexity to this aspect. In addition, Na\textsubscript{V} \(\beta\) subunits can also influence certain potassium currents, thereby contributing to cross-talk between Na\textsubscript{V} and potassium channels. Progress on this topic may be accomplished by investigating the structural determinants of the interaction and affinity between \(\alpha\) and \(\beta\) subunits within the Na\textsubscript{V} channel [37,39]. For instance, non-covalently bound \(\beta\)1 and \(\beta\)3 subunits affect the conformational dynamics of Na\textsubscript{V}1.5 by binding, through their extracellular and TMDs, to the voltage-sensing domains within domains III and IV of Na\textsubscript{V}1.5, thereby modulating ionic current kinetics and cell excitability [30].

Next, we will focus specifically on regulation of \(\beta\)2 trafficking, and how that could influence localization of Na\textsubscript{V}1.5, an aspect of key importance in cellular excitability and electrical coupling of the heart.
2. The β2 Subunit

2.1. Sequence and Domain Architecture of β2

Proper traffic and localization of β2 to subdomains of the plasma membrane is likely determined by its sequence motifs. Moreover, the interaction between β2 and NaV1.5, as well as with other channel-regulatory molecules, must be relevant to determine the correct localization of NaV1.5, and therefore the functionality of the NaV channel. To examine this aspect, a biochemical dissection of β2 should be performed. β2 is a type I transmembrane protein with an extracellular, immunoglobulin (Ig)-like loop, having a role in cell adhesion [12], a single TMD, and a short cytoplasmic tail [40] (Figure 4). The extracellular loop, maintained by an intramolecular disulfide bond between Cys-50 and (Ig)-like loop, having a role in cell adhesion [12], a single TMD, and a short cytoplasmic tail [40] (Figure 4). The extracellular loop, maintained by an intramolecular disulfide bond between Cys-50 and Cys-127 [29], has three potential N-glycosylation sites, that is, Asn-42, Asn-66 and Asn-74 [38]. Within this region, a third cysteine, Cys-55, establishes a disulfide bond with the α subunit [29]. On the other hand, the short intracellular C-terminal domain has two possible phosphorylation sites, i.e., Ser-192 and Thr-204 [41] (based on UniProtKB accession number O60939, corresponding to human SCN2B).

2.2. Trafficking of β2 and Its Role within the NaV Channel

The case of β2 is of particular interest concerning control of channel localization, since it is believed to influence localization of NaV1.5 at a post-Golgi site, on its targeting to the cell surface [42,43]. In addition, we have described the first mutation associated with BrS in SCN2B [32], the gene encoding β2. Our data have shown that the β2 D211G mutation (a substitution of Asp by Gly) causes an I\textsubscript{Na} reduction of ~40% due to decreased cell surface levels of Na\textsubscript{V}1.5 [32,44]. Consistent with these data, it has been found that Scn2b deletion in mice entails, both in ventricular myocytes [45] and in primary cultures of hippocampal neurons [46], a comparable 40% decrease in surface levels of the α subunit and, as a result, of the I\textsubscript{Na}. Notably, β2 must associate with the α subunit for targeting to the nodes of Ranvier and the axon initial segment of the α/β2 complex [29].

![Figure 4. Sequence and domain architecture of the β2 subunit. Of its 215 amino acids, the first 29 correspond to the predicted N-terminal (N-ter.) signal peptide [41]. It is worth noting the extracellular immunoglobulin (Ig)-like loop. The transmembrane domain (TMD), which expands along ~20 residues, and probably associates with lipid rafts, is followed by a short C-terminal domain. Asterisks denote the approximate location of cleavage sites by β-secretase (*) and γ-secretase (**). Pathogenic mutations, i.e., the atrial fibrillation-associated R28Q and R28W, and the BrS-associated D211G, are shown in pink background; see the text for more details.](image-url)
We have shown that β2, exogenously expressed in Madin-Darby canine kidney (MDCK) cells, localizes in a polarized way at the apical plasma membrane domain [44]. In both MDCK cells and in cardiomyocyte-derived HL-1 cells, localization of Na\textsubscript{V}1.5 at the surface is strengthened by β2, but not by the subunit carrying the D211G BrS mutation. Regarding differential surface distribution, it is noteworthy the case of the β1 subunit, whose Tyr phosphorylation regulates its localization in sarcolemmal subdomains. As shown in mouse ventricular myocytes, Na\textsubscript{V} channels at the ID consist of Na\textsubscript{V}1.5 and pYβ1, in close association with N-cadherin and Cx43, while channels in T tubules would be formed by other Na\textsubscript{V} isoforms, such as Na\textsubscript{V}1.1 and Na\textsubscript{V}1.6, linked with unphosphorylated β1, and associated with ankyrin-B [26]. Understanding the mechanisms that determine these interactions is of the utmost importance, since the differential location of Na\textsubscript{V} channels in subregions of the sarcolemma certainly influences conduction velocity and cardiac impulse propagation [20] (see Figure 3).

It is not known how β2 is transported to the cell surface; more specifically, it remains to be addressed how β2 is targeted preferentially to the apical region in MDCK cells. In fact, understanding how apical targeting signals are recognized in proteins is the focus of intense study. Such recognition can take place by association of the protein’s TMD with lipid rafts. It can also occur via N- or O-glycosylation of the luminal domain, and its consequent interaction with galectins (proteins that bind glycoprotein carbohydrates). Additional elements have been implicated, including certain Rab GTPases (belonging to the Ras superfamily of small GTPases), microtubule motor proteins, and elements of the actin cytoskeleton [47,48].

Based on these considerations, it is tempting to speculate that apical β2 localization may have a parallelism with its location at the nodes of Ranvier and the axon initial segment, where it interacts with the α subunit [29]. If β2 similarly distributes in specialized sarcolemmal regions, it would help to define, at least in part, the precise Na\textsubscript{V}1.5 location also at the cardiomyocyte surface. It is important to note that it remains to be investigated whether targeting of β2 to such surface regions, and its surface dynamics, potentially involving its endocytosis and turnover, are regulated by remodeling of the lipid bilayer, glycosylation, and/or dimerization/oligomerization. In this regard, we have recently found that N-glycosylation of β2 is indeed necessary for its efficient trafficking and localization to the plasma membrane; importantly, non-glycosylated β2 does not promote surface localization of Na\textsubscript{V}1.5 [49].

2.3. Functions of β2

As demonstrated in Scn2b knockout mice, β2 has essential in vivo functions in maintenance of neuronal excitability. However, it was not found necessary for Na\textsubscript{V} channel expression, or for survival, since knockouts develop normally, their neuronal function and morphology appear normal, and also their life expectancy. Yet, β2 is necessary for voltage-dependent inactivation of the I\textsubscript{Na} and for maintenance of Na\textsubscript{V} channel levels at the plasma membrane of the neuronal soma and in myelinated axons. The lack of β2 leads to hyperexcitability and to a decrease of the threshold to suffer seizures, possibly due to reduced excitability of inhibitory interneurons [46].

Concerning cardiac function, Scn2b knockout mice suffer from ventricular and atrial arrhythmias [45], which is consistent with SCN2B mutations described in humans [32,50]. In fact, these mice seem to reproduce some aspects of BrS, and it has been proposed that they could be very useful for modeling aspects of human ventricular arrhythmias with a greater susceptibility to atrial arrhythmia [45]. Intriguingly, a more recent report conclusively demonstrates that both β2 and β4 (unlike β1 and β3) are virtually undetected in ventricle of canine heart, implying that these subunits unlikely have any contribution to the regional manifestation of BrS, typically affecting the right ventricle rather than the left one [51].

Interestingly, human β2 can be sequentially cleaved by secretases; cleavage of β2 takes place analogously to the processing of the amyloid precursor protein (APP), whose amyloidogenic cleavage is cause and aggravation of the pathogenesis in Alzheimer’s disease [52]. In fact, β2 cleavage by α-secretase, and subsequently by γ-secretase, appears required for cell-cell adhesion and migration of β2-expressing cells [53]. In this regard, its extracellular domain, which confers β2 features of
cell adhesion molecule (CAM), has been shown to interact via homophilic, and also heterophilic connections, by which it would bind the extracellular matrix proteins tenasin-R and tenasin-C, and also the β1 subunit, thereby functioning as a CAM [54,55]. Because β subunits are cell surface glycoproteins expressed during key periods of neuronal development, those earlier studies led to the hypothesis that they likely have a dual role, i.e., regulating the ion channel and functioning as CAMs. Such role on cell adhesion appears independent of their action on the channel α subunit, and would be responsible of bringing out an important connection between the extracellular environment and the cytoskeleton, for instance, by means of AnK recruitment, which could have important implications in neural development [56].

The γ-secretase cleavage site in β2 [57], and probably that for β-secretase as well, appears to be conserved [58,59]. At least in mouse, the four β subunits (β1-4) can actually be processed by β-secretase, i.e., the β-site APP cleaving enzyme (BACE1) [59]. The cleaved intracellular domain of β2, as shown in neurons, is translocated to the nucleus to participate in transcriptional regulation of the α subunit, and possibly of other genes [52]. These results have been linked with observations from the null phenotype in mice. Since the Scn2b knockout mice displays uncontrolled fibrosis, i.e., cell replacement with fibrous connective tissue, it has been suggested that the β2 intracellular domain may regulate genes inhibiting atrial fibrosis [45].

Such remarkable finding reported over 10 years ago led to the conclusion that the β2 intracellular domain acts as a transcriptional activator for Na\(_V\)1.1, although the increased α subunit accumulated intracellularly, while its cell surface levels were reduced [52]. Subsequently, these authors reported that BACE1 null mice have increased Na\(_V\)1.2 surface levels, explained as a potential compensatory mechanism for the reduced surface Na\(_V\)1.1 level. However, no changes in mRNA levels for Na\(_V\)1.2 were detected [60]. This issue remains controversial as the phenotype of BACE1 null mice, i.e., susceptibility to seizures, could not be explained by alteration in expression and localization of Na\(_V\)1.2 or Na\(_V\)1.6, since protein levels of these α subunits remained unaltered and their distribution could not be correlated with the phenotype of these mice [61]. Interestingly, further work has shown that BACE1 can also have a non-enzymatic role on α, implying an influence on the electrical behavior of excitable cells independent of its proteolytic activity. Specifically, BACE1 was found to act as an accessory subunit of Na\(_V\)1.2, mimicking β2 in the α/β channel complex. This feature of BACE1, i.e., acting as an accessory β subunit of Na\(_V\), and also potassium channels, would influence channel function, having an impact on cellular excitability and brain network activity, and at the same time may help explaining previous data. Importantly, this aspect opens a new area of study of BACE1 in physiology and pathology (reviewed in [62]).

Altogether, the published data provide strong evidence supporting a role of β subunits as signaling molecules involved in cell adhesion, migration, and neurite outgrowth [12]. In this regard, β1 was conclusively shown to promote neurite outgrowth in vivo through a signaling process triggered by trans-homophilic cell adhesion and association with lipid rafts, which was suggested to be essential for postnatal development of the central nervous system [63]. Within the context of cardiac function, an important result in this regard is the recent finding showing that β1, by mediating cell-cell adhesion, contributes to spreading of the AP along ventricular cardiomyocytes [64]. This work shows that β1 facilitates coupling of adjacent cells for ion exchange, being located within clefts of the perinexus, i.e., the narrow stretch of membranes closely apposed and adjacent to the gap junctions. By super-resolution optical microscopy, the authors concluded that β1 is located within Na\(_V\)1.5-enriched nanodomains of the ID, however, it was seen clearly away from the fascia adherens areas rich in N-cadherin [64].

Here, we propose that β2 may have similar, yet to be discovered functions in adhesion and signaling also in cardiomyocytes. Investigating these potential features could help to understand better the role of β2 in specialized subdomains of the sarcolemma, both within and outside the Na\(_V\) channel. Indeed, β2 also binds laminin, which is the most abundant CAM in the extracellular matrix of the peripheral nervous system. In this regard, it has been suggested that β2 overexpression in prostate cancer mediates the neoplastic invasion of the nerves, which is believed to be a common pathway for...
cancer metastasis [65]. Intriguingly, this feature of β2 may have a connection with previous observation showing that β2 overexpression causes an increase of the cell surface membrane in Xenopus oocytes, which was then explained by increasing fusion of intracellular vesicles with the plasma membrane [40].

3. Overview and Working Hypotheses

In the context of the heart, the current data support the idea that β2 has a role in regulating localization and function of the Nav1 channel in cardiomyocytes. In MDCK cells, a model system that we have used to imitate the polarized cardiomyocytes [18], β2 is located at the apical surface [44]. This distribution may have a correspondence with its preferential targeting to the neural nodes of Ranvier and the axon initial segment, where it interacts with the α subunit [29]. Given the importance of the α/β2 link, it is fundamental to understand how alterations in β2 may affect its localization and that of Nav1.5 at the cell surface. In this regard, we have analyzed the influence of β2 on localization and function of the Nav1 channel in polarized MDCK cells. Our data show that targeting of β2 to the cell surface is affected if N-glycosylation is abolished, causing retention of β2 in the ER. A small fraction of the triple non-glycosylated β2 mutant, that is, N42Q/N66Q/N74Q, can still reach the cell surface by bypassing the Golgi complex, and is correctly targeted to the apical domain. However, it is important to underline that it does not promote surface localization of Nav1.5, since coexpression of this mutant causes a reduction in surface levels of Nav1.5 [49] (Figure 5). Therefore, it is clearly defective in regulating Nav1.5 surface localization, which is a well-accepted function of β2 in the heart [12]. Yet, we have seen that a single N-glycosylation is sufficient for β2 to reach the cell surface and to ensure efficient Nav1.5 localization [49]. To perform this role, we suggest that N-glycosylation in β2 is necessary for its recognition through galectins, which would guide β2 to the proper cell surface domain [66].

**Figure 5.** N-glycosylation of β2 is necessary for its targeting to the cell surface and to promote surface localization of Na\(_{v}\)1.5. Proper β2 trafficking is determinant for Na\(_{v}\)1.5 localization to the cell surface, and specifically, to the apical plasma membrane (API) in polarized MDCK cells. Unglycosylated (UNG; N42Q/N66Q/N74Q) β2 is retained in the endoplasmic reticulum (ER), often seen together with Nav1.5. By bypassing the Golgi apparatus (G), a fraction of the mutant can reach the cell surface (dotted arrow), but at a rate of only approximately one-third of that of the wild type. In addition, it is defective in promoting surface localization of Na\(_{v}\)1.5. BAS, basolateral surface; TJ, tight junctions.

For the β1 subunit, it has been proposed that palmitoylation is a possible mechanism for its adequate surface localization and consequent anchorage to lipid rafts [28]. Along these lines, we suggest that the TMD influences the localization of β2 within surface subdomains, which would also take place by association with these cholesterol-rich regions, and would possibly be regulated by the TMD length [67]. In this regard, our ongoing work shows that the apical distribution of β2 in MDCK cells is altered upon cholesterol depletion [68]. In primary cortical neurons, all four β subunits (β1-4) have in fact been found enriched in detergent resistant membranes by subcellular fractionation, implying their
preferential association with lipid rafts [59]. On the other hand, it remains to be addressed the possible contribution of the Ig domain [29,69] in disulfide bond-mediated dimerization/oligomerization of β2 [70] and, consequently, in β2 targeting to certain surface domains.

We propose that mutations associated with β2—some of which undoubtedly linked to disease [32,50]—alter its dynamics at the membrane, negatively affecting localization and function of the NaV channel. As previously seen [44–46], mutated β2, or its absence, negatively affects NaV1.5 traffic from the ER to the plasma membrane. A mutation in β2 may cause its intracellular retention. In the case of the BrS-associated D211G mutation, β2 reaches the plasma membrane normally. However, similar to unglycosylated β2 [49], this mutant is defective in promoting NaV1.5 trafficking to the surface [44]. In addition to β2 N-glycosylation, which should ensure NaV1.5 chaperoning for proper folding, we propose that there are elements in the cytoplasmic domain of β2 potentially implicated on regulating NaV1.5 localization. In this regard, dynamics in β2 phosphorylation could potentially influence recruitment of adapter proteins, such as AnkG [19], thereby affecting targeting of the NaV channel to the right surface subdomain. Given its proximity, the D211G mutation could influence potential phosphorylation predicted to take place in C-terminal residues [41] (see Figure 4). Support for this idea comes from previous work showing that the β2 intracellular domain, possibly interacting with AnkG, allows the heterophilic interaction with the extracellular domain of β1, thereby stabilizing extracellular cell adhesion. The region in β2 required was mapped, and encompasses two Thr residues, i.e., T198 and T204, that belong to a consensus sequence for potential phosphorylation by casein kinase II, and thereby may be critical for AnkG interaction, in analogy to Tyr-phosphorylated β1 [71,72].

Additional evidence suggesting that there is an indirect link between NaV1.5 and β subunits implicated on regulating localization of α also comes from earlier work showing that the cytoplasmic domain of β subunits may not have much influence on α/β interaction in heterologous cell systems. Thus, a β1 chimera bearing the intracellular domain of β2 overlapped strongly with NaV1.5, supposedly in intracellular compartments [73], similarly as β1 does, but in contrast to β2, which is efficiently targeted to the cell surface [42]. Moreover, recent data obtained by cryo-electron microscopy confirmed that direct α/β2 interaction takes place essentially through extracellular disulfide binding, i.e., at Cys-55, as previously shown [29], in addition to hydrogen bonding with Tyr-56 and Arg-135, although the latter, connecting with the Ig loop, are likely less stable interactions [74,75]. Interestingly, a previous report presenting 3D structural data of the β2 extracellular region obtained by X-ray crystallography revealed the exact points of contact with the α subunit and indicated that β2 is unique among the NaV β subunits in that it contains a second intrasubunit disulfide bond, via Cys-72 and Cys-75, in addition to the common Cys-50 and Cys-127 bond, conserved in its β counterparts, yet this peculiarity may have a yet to be elucidated function [76]. On the whole, we suggest that, at least in part, the action of β2 on α, and in particular on NaV1.5, may take place indirectly.

4. Limitations: The Cell Model System

Carrying out studies in immortalized cell lines, such as Human Embryonic Kidney 293 cells, Chinese Hamster Ovary cells, or MDCK cells, represents an obvious limitation to recapitulate the biology of the β2 subunit in the cardiomyocyte, or in other excitable cells. Like cardiomyocytes, MDCK cells are polarized, but unlike those, they are epithelial cells. On the other hand, HL-1 cells are of cardiac origin, albeit they are not polarized. In general, mechanisms governing trafficking have been studied in cell lines growing in artificial environments, such as monolayers attached on a substrate, or embedded in a matrix resembling the extracellular milieu. These setups are suitable for analyzing many aspects addressed here. However, most of these cell lines have the obvious limitation that they are not excitable. Even HL-1 cells, which have endogenous I\textsubscript{Na} [77], do not express β subunits and have very low levels of NaV1.5 ([44], and our unpublished data), and must also be transfected to study sorting and targeting of the NaV channel. Likewise, most of these cell lines probably lack specific channel-associated proteins, as well as components of the machinery required for sorting, targeting, or membrane anchoring of channel subunits and, therefore, for their proper localization.
in the cardiomyocyte. Therefore, we must keep in mind that when studying the role of β subunits, their trafficking, or interaction with α, it is quite possible that some observed effects differ from what really occurs in a cardiomyocyte or in other excitable cells. Definitely, this issue should be addressed by researchers in the field, and a considerable effort must be put on developing more suitable models to analyze trafficking of the NaV channel subunits and also of the channel’s biophysical properties.

5. Implications of Research on the NaV Channel β Subunits

Research projects strictly focused on the biological aspects, as those with a strong relevance to clinical aspects, are valid to address the aspects discussed here. Studying the mechanisms that may be altered in heart disease poses to address one of the main challenges of society, that is, human health. A key hypothesis is that alterations in localization of components of the NaV channel complex convey a risk of arrhythmia and, therefore, are potentially associated with important cardiac pathologies.

Altogether, it is of utmost importance that findings in the field lead to a better understanding of how subunits of the NaV channel correctly localize. Undoubtedly, growing knowledge on this aspect will provide a better picture on the link between cell excitability and the electrical coupling in the heart, thereby contributing to a better knowledge of how arrhythmias develop.

In summary, future studies should be aimed to understanding better the genetic factors that determine phenotype variability. We are convinced that data generated in this field will be very useful for risk stratification of the patient and therefore to predict heart disease. This should contribute to early diagnosis of disease in asymptomatic individuals potentially at risk of SCD and to improve treatment therapies, also avoiding a fatal event in patients already suffering from heart disease.

Author Contributions: Conceptualization, M.V. and E.C.; investigation, M.V. and E.C.; resources, R.B.; writing—original draft preparation, M.V.; writing—review and editing, M.V., E.C. and R.B.; funding acquisition, R.B.

Funding: This research and the APC were funded by “La Caixa” Foundation, a grant to R.B (number N/A).

Acknowledgments: E.C. is recipient of a predoctoral fellowship (FI_B 00071) from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR)—Generalitat de Catalunya. We also thank the University of Girona and the Spanish Instituto de Salud Carlos III (ISCIII); the CIBERCV is an initiative of the ISCIII from the Spanish Ministerio de Ciencia, Innovació y Universidades.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Rubart, M.; Zipes, D.P. Mechanisms of sudden cardiac death. J. Clin. Invest. 2005, 115, 2305–2315. [CrossRef] [PubMed]
2. Mehra, R. Global public health problem of sudden cardiac death. J. Electrocardiol. 2007, 40, S118–S122. [CrossRef] [PubMed]
3. Campuzano, O.; Beltran-Alvarez, P.; Iglesias, A.; Scornik, F.; Perez, G.; Brugada, R. Genetics and cardiac channelopathies. Genet. Med. 2010, 12, 260–267. [CrossRef] [PubMed]
4. Napolitano, C.; Priori, S.G. Brugada syndrome. Orphanet J. Rare Dis. 2006, 1, 35. [CrossRef]
5. Bezzina, C.R.; Rook, M.B.; Wilde, A.A. Cardiac sodium channel and inherited arrhythmia syndromes. Cardiovasc. Res. 2001, 49, 257–271. [CrossRef]
6. Brugada, P.; Brugada, J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. A multicenter report. J. Am. Coll. Cardiol. 1992, 20, 1391–1396. [CrossRef]
7. Bastiaenen, R.; Behr, E.R. Sudden death and ion channel disease: Pathophysiology and implications for management. Heart 2011, 97, 1365–1372. [CrossRef]
8. Amin, A.S.; Asghari-Roodsari, A.; Tan, H.L. Cardiac sodium channelopathies. Pflug. Arch. 2010, 460, 223–237. [CrossRef]
9. Wang, Q.; Shen, J.; Splawski, I.; Atkinson, D.; Li, Z.; Robinson, J.L.; Moss, A.J.; Towbin, J.A.; Keating, M.T. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. *Cell* 1995, 80, 805–811. [CrossRef]

10. Ruan, Y.; Liu, N.; Priori, S.G. Sodium channel mutations and arrhythmias. *Nat. Rev. Cardiol.* 2009, 6, 337–348. [CrossRef]

11. Abriel, H.; Kass, R.S. Regulation of the voltage-gated cardiac sodium channel Nav1.5 by interacting proteins. *Trends Cardiovasc. Med.* 2005, 15, 35–40. [CrossRef] [PubMed]

12. O’Malley, H.A.; Isom, L.L. Sodium channel beta subunits: emerging targets in channelopathies. *Annu. Rev. Physiol.* 2015, 77, 481–504. [CrossRef] [PubMed]

13. Rook, M.B.; Evers, M.M.; Vos, M.A.; Bierhuizen, M.F. Biology of cardiac sodium channel Nav1.5 expression. *Cardiovasc. Res.* 2012, 93, 12–23. [CrossRef]

14. Perez-Hernandez, M.; Matamoros, M.; Alfayate, S.; Nieto-Marin, P.; Utrilla, R.G.; Tinaquero, D.; de Andres, R.; Crespo, T.; Ponce-Balbuena, D.; Willis, B.C.; et al. Brugada syndrome trafficking-defective Nav1.5 channels can trap cardiac Kir2.1/2.2 channels. *JCI Insight* 2018, 3, 96291. [CrossRef] [PubMed]

15. Abriel, H. Cardiac sodium channel Na(v)1.5 and interacting proteins: Physiology and pathophysiology. *J. Mol. Cell Cardiol.* 2010, 48, 2–11. [CrossRef]

16. Liu, M.; Yang, K.C.; Dudley, S.C., Jr. Cardiac sodium channel mutations: Why so many phenotypes? *Nat. Rev. Cardiol.* 2014, 11, 607–615. [CrossRef] [PubMed]

17. Ponce-Balbuena, D.; Guerrero-Serna, G.; Valdivia, C.R.; Caballero, R.; Diez-Guerra, F.J.; Jimenez-Vazquez, E.N.; Ramirez, R.J.; Monteiro da Rocha, A.; Herron, T.J.; Campbell, K.F.; et al. Cardiac Kir2.1 and Nav1.5 channels traffic together to the sarcolemma to control excitability. *Circ. Res.* 2018, 122, 1501–1516. [CrossRef]

18. Balse, E.; Steele, D.F.; Abriel, H.; Coulombe, A.; Fedida, D.; Hatem, S.N. Dynamic of ion channel expression at the plasma membrane of cardiomyocytes. *Physiol. Rev.* 2012, 92, 1317–1358. [CrossRef]

19. Mohler, P.J.; Rivolta, I.; Napolitano, C.; LeMaillet, G.; Lambert, S.; Priori, S.G.; Bennett, V. Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. *Proc. Natl. Acad. Sci. USA* 2004, 101, 17533–17538. [CrossRef]

20. Petitprez, S.; Zmoos, A.F.; Ogrodnik, J.; Balse, E.; Raad, N.; El-Haou, S.; Albesa, M.; Bittihn, P.; Luther, S.; Lehnhert, S.E.; et al. SAP97 and dystrophin macromolecular complexes determine two pools of cardiac sodium channels Nav1.5 in cardiomyocytes. *Circ. Res.* 2011, 108, 294–304. [CrossRef]

21. Sato, P.Y.; Coombs, W.; Lin, X.; Nekrasova, O.; Green, K.J.; Isom, L.L.; Taffet, S.M.; Delmar, M. Interactions between ankyrin-G, plakophilin-2, and Connexin43 at the cardiac intercalated disc. *Circ. Res.* 2011, 109, 193–201. [CrossRef] [PubMed]

22. Bennett, V.; Healy, J. Being there: Cellular targeting of voltage-gated sodium channels in the heart. *J. Cell Biol.* 2008, 180, 13–15. [CrossRef] [PubMed]

23. Lowe, J.S.; Palygin, O.; Bhasin, N.; Hund, T.J.; Boyden, P.A.; Shibata, E.; Anderson, M.E.; Mohler, P.J. Voltage-gated Nav channel targeting in the heart requires an ankyrin-G dependent cellular pathway. *J. Cell Biol.* 2008, 180, 173–186. [CrossRef] [PubMed]

24. Agullo-Pascual, E.; Lin, X.; Leo-Macias, A.; Zhang, M.; Liang, F.X.; Li, Z.; Pfenniger, A.; Lubkemeier, I.; Keegan, S.; Fenyo, D.; et al. Super-resolution imaging reveals that loss of the C-terminus of connexin43 limits microtubule plus-end capture and Nav1.5 localization at the intercalated disc. *Cardiovasc. Res.* 2014, 104, 371–381. [CrossRef] [PubMed]

25. Rougier, J.S.; Essers, M.C.; Gillet, L.; Guichard, S.; Sonntag, S.; Shmerling, D.; Abriel, H. A distinct pool of Nav1.5 channels at the lateral membrane of murine ventricular cardiomyocytes. *Front. Physiol.* 2019, 10, 834. [CrossRef] [PubMed]

26. Malhotra, J.D.; Thyagarajan, V.; Chen, C.; Isom, L.L. Tyrosine-phosphorylated and nonphosphorylated sodium channel beta1 subunits are differentially localized in cardiac myocytes. *J. Biol. Chem.* 2004, 279, 40748–40754. [CrossRef] [PubMed]

27. Gillet, L.; Shy, D.; Abriel, H. Elucidating sodium channel Nav1.5 clustering in cardiac myocytes using super-resolution techniques. *Cardiovasc. Res.* 2014, 104, 231–233. [CrossRef]

28. Brackenbury, W.J.; Isom, L.L. Na channel beta subunits: Overachievers of the ion channel family. *Front. Pharmacol.* 2011, 2, 53. [CrossRef]
29. Chen, C.; Calhoun, J.D.; Zhang, Y.; Lopez-Santiago, L.; Zhou, N.; Davis, T.H.; Salzer, J.L.; Isom, L.L. Identification of the cysteine residue responsible for disulfide linkage of Na⁺ channel alpha and beta2 subunits. J. Biol. Chem. 2012, 287, 39061–39069. [CrossRef]

30. Zhu, W.; Voelker, T.L.; Varga, Z.; Schubert, A.R.; Nerbonne, J.M.; Silva, J.R. Mechanisms of noncovalent beta subunit regulation of Na⁺ channel gating. J. Gen. Physiol. 2017, 149, 813–831. [CrossRef]

31. Molinarolo, S.; Granata, D.; Carnevale, V.; Ahern, C.A. Mining protein evolution for insights into mechanisms of protein evolution. Nucleic Acids Res. 2015, 43, 3427–3443. [CrossRef] [PubMed]

32. Johnson, D.; Bennett, E.S. Isoform-specific effects of the beta2 subunit on voltage-gated sodium channel gating. J. Biol. Chem. 2006, 281, 25875–25881. [CrossRef] [PubMed]

33. Namadurai, S.; Yereddi, N.R.; Cusdin, F.S.; Huang, C.L.; Chirgadze, D.Y.; Jackson, A.P. Structure and function of the beta 2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. Open Biol. 2015, 5, 140192. [CrossRef]

34. Schmidt, J.W.; Catterall, W.A. Biosynthesis and processing of the alpha subunit of the voltage-sensitive sodium channel in rat brain neurons. Cell 1986, 46, 437–444. [CrossRef]

35. Bao, Y.; Willis, B.C.; Frasier, C.R.; Lopez-Santiago, L.F.; Lin, X.; Ramos-Mondragon, R.; Auerbach, D.S.; Chen, C.; Wang, Z.; Anumonwo, J.; et al. Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits. Proc. Natl. Acad. Sci. USA 2002, 99, 17072–17077. [CrossRef]

36. Stoops, E.H.; Caplan, M.J. Trafficking to the apical and basolateral membranes in polarized epithelial cells. J. Am. Soc. Nephrol. 2014, 25, 1375–1386. [CrossRef]

37. Weisz, O.A.; Rodriguez-Boulan, E. Apical trafficking in epithelial cells: Signals, clusters and motors. J. Cell Sci. 2009, 122, 4253–4266. [CrossRef]
49. Cortada, E.; Brugada, R.; Verges, M. N-glycosylation of the voltage-gated sodium channel beta2 subunit is required for efficient trafficking of NaV1.5/beta2 to the plasma membrane. *J. Biol. Chem.* 2019, 294. [CrossRef]

50. Watanabe, H.; Darbar, D.; Kaiser, D.W.; Jiramongkolchai, K.; Chopra, S.; Donahue, B.S.; Kannankeril, P.J.; Roden, D.M. Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation. *Circ. Arrhythm. Electrophysiol.* 2009, 2, 268–275. [CrossRef]

51. Calloe, K.; Aistrup, G.L.; Di Diego, J.M.; Goodrow, R.J.; Treat, J.A.; Cordeiro, J.M. Interventricular differences in sodium current and its potential role in Brugada syndrome. *Physiol. Rep.* 2018, 6, e13787. [CrossRef]

52. Kim, D.Y.; Carey, B.W.; Wang, H.; Ingano, L.A.; Birsh tok, A.M.; Wertz, M.H.; Pettingell, W.H.; He, P.; Lee, V.M.; Woelf, C.J.; et al. BACE1 regulates voltage-gated sodium channels and neuronal activity. *Nat. Cell Biol.* 2007, 9, 755–764. [CrossRef] [PubMed]

53. Kim, D.Y.; Ingano, L.A.; Carey, B.W.; Pettingell, W.H.; Kovacs, D.M. Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. *J. Biol. Chem.* 2005, 280, 23251–23261. [CrossRef] [PubMed]

54. Xiao, Z.C.; Ragsdale, D.S.; Malhotra, J.D.; Mattei, L.N.; Braun, P.E.; Schachner, M.; Isom, L.L. Tenascin-R is a functional modulator of sodium channel beta subunits. *J. Biol. Chem.* 1999, 274, 26511–26517. [CrossRef] [PubMed]

55. Srinivasan, J.; Schachner, M.; Catterall, W.A. Interaction of voltage-gated sodium channels with the extracellular matrix molecules tenasin-C and tenasin-R. *Proc. Natl. Acad. Sci. USA* 1998, 95, 15753–15757. [CrossRef]

56. Malhotra, J.D.; Kazen-Gillespie, K.; Hortsch, M.; Isom, L.L. Sodium channel beta subunits mediate homophilic cell adhesion and recruit ankyrin to points of cell-cell contact. *J. Biol. Chem.* 2000, 275, 11383–11388. [CrossRef]

57. Chopra, S.S.; Watanabe, H.; Zhong, T.P.; Roden, D.M. Molecular cloning and analysis of zebrafish voltage-gated sodium channel beta subunit genes: Implications for the evolution of electrical signaling in vertebrates. *BMC Evol. Biol.* 2007, 7, 113. [CrossRef]

58. Gersbacher, M.T.; Kim, D.Y.; Bhattacharyya, R.; Kovacs, D.M. Identification of BACE1 cleavage sites in human voltage-gated sodium channel beta 2 subunit. *Mol. Neurodegener.* 2010, 5, 61. [CrossRef]

59. Wong, H.K.; Sakurai, T.; Oyama, F.; Kaneko, K.; Wada, K.; Miyazaki, M.; De Strooper, B.; Saftig, P.; Nukina, N. beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. *J. Biol. Chem.* 2005, 280, 23009–23017. [CrossRef]

60. Kim, D.Y.; Gersbacher, M.T.; Inquimbert, P.; Kovacs, D.M. Reduced sodium channel Na(v)1.1 levels in BACE1-null mice. *J. Biol. Chem.* 2011, 286, 8106–8116. [CrossRef]

61. Hitt, B.D.; Jaramillo, T.C.; Chetkovich, D.M.; Vassar, R. BACE1/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. *Mol. Neurodegener.* 2010, 5, 31. [CrossRef]

62. Lehnert, S.; Hartmann, S.; Hessler, S.; Adelsberger, H.; Huth, T.; Alzheimer, C. Ion channel regulation by beta-secretase BACE1 - enzymatic and non-enzymatic effects beyond Alzheimer’s disease. *Channels* 2016, 10, 365–378. [CrossRef] [PubMed]

63. Brackenbury, W.J.; Davis, T.H.; Chen, C.; Slat, E.A.; Detrow, M.J.; Dickendesher, T.L.; Ranscht, B.; Isom, L.L. Voltage-gated Na+ channel beta1 subunit-mediated neurite outgrowth requires Fyn kinase and contributes to postnatal CNS development in vivo. *J. Neurosci.* 2008, 28, 3246–3256. [CrossRef] [PubMed]

64. Veeraraghavan, R.; Hoeker, G.S.; Alvarez-Laviada, A.; Hoagland, D.; Wan, X.; King, D.R.; Sanchez-Alonso, J.; Chen, C.; Jourdan, J.; Isom, L.L.; et al. The adhesion function of the sodium channel beta subunit (beta1) contributes to cardiac action potential propagation. *eLife* 2018, 7, e37610. [CrossRef] [PubMed]

65. Jansson, K.H.; Castillo, D.G.; Morris, J.W.; Boggs, M.E.; Czymmek, K.J.; Adams, E.L.; Schramm, L.P.; Sikes, R.A. Identification of beta-2 as a key cell adhesion molecule in PCa cell neurotropic behavior: A novel ex vivo and biophysical approach. *PLoS ONE* 2014, 9, e89408. [CrossRef]

66. Castillon, G.A.; Michon, L.; Watanabe, R. Apical sorting of lysoGPI-anchored proteins occurs independent of association with detergent-resistant membranes but dependent on their N-glycosylation. *Mol. Biol. Cell* 2013, 24, 2021–2033. [CrossRef]

67. Sharpe, H.J.; Stevens, T.J.; Munro, S. A comprehensive comparison of transmembrane domains reveals organelle-specific properties. *Cell* 2010, 142, 158–169. [CrossRef]
68. Cortada, E.; Serradesanferm, R.; Brugada, R.; Verges, M. Role of lipid raft domains in plasma membrane dynamics of the voltage-gated sodium channel β2 subunit. (unpublished work).
69. Wimmer, V.C.; Reid, C.A.; Mitchell, S.; Richards, K.L.; Scaf, B.B.; Leaw, B.T.; Hill, E.L.; Royeck, M.; Horstmann, M.T.; Cromer, B.A.; et al. Axon initial segment dysfunction in a mouse model of genetic epilepsy with febrile seizures plus. J. Clin. Investig. 2010, 120, 2661–2671. [CrossRef]
70. Namadurai, S.; Balasuriya, D.; Rajappa, R.; Wiemhofer, M.; Stott, K.; Klingauf, J.; Edwardson, J.M.; Chirgadze, D.Y.; Jackson, A.P. Crystal structure and molecular imaging of the Nav channel beta3 subunit indicates a trimeric assembly. J. Biol. Chem. 2014, 289, 10797–10811. [CrossRef]
71. McEwen, D.P.; Isom, L.L. Heterophilic interactions of sodium channel beta1 subunits with axonal and glial cell adhesion molecules. J. Biol. Chem. 2004, 279, 52744–52752. [CrossRef]
72. McEwen, D.P.; Meadows, L.S.; Chen, C.; Thyagarajan, V.; Isom, L.L. Sodium channel beta1 subunit-mediated modulation of Nav1.2 currents and cell surface density is dependent on interactions with contactin and ankyrin. J. Biol. Chem. 2004, 279, 16044–16049. [CrossRef]
73. Zimmer, T.; Benndorf, K. The intracellular domain of the beta 2 subunit modulates the gating of cardiac Nav1.5 channels. Biophys. J. 2007, 92, 3885–3892. [CrossRef][PubMed]
74. Shen, H.; Liu, D.; Wu, K.; Lei, J.; Yan, N. Structures of human Nav1.7 channel in complex with auxiliary subunits and animal toxins. Science 2019, 363, 1303–1308. [CrossRef][PubMed]
75. Pan, X.; Li, Z.; Huang, X.; Huang, G.; Gao, S.; Shen, H.; Liu, L.; Lei, J.; Yan, N. Molecular basis for pore blockade of human Na(+) channel Nav1.2 by the mu-conotoxin KIIIA. Science 2019, 363, 1309–1313. [CrossRef][PubMed]
76. Das, S.; Gilchrist, J.; Bosmans, F.; Van Petegem, F. Binary architecture of the Nav1.2-beta2 signaling complex. eLife 2016, 5. [CrossRef][PubMed]
77. Claycomb, W.C.; Lanson, N.A., Jr; Stallworth, B.S.; Egeland, D.B.; Delcarpio, J.B.; Bahinski, A.; Izzo, N.J., Jr. HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. USA 1998, 95, 2979–2984. [CrossRef]